Paul L. Berns, Director at Cellectar Biosciences, Inc. (CLRB), bought 234,742 shares at $2.12 ($498K) on 2016-04-20, disclosed to the SEC on 2016-04-21.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.12 | 117,371 | $249K | 50.0% |
| 2 | $2.12 | 117,371 | $249K | 50.0% |
| Total | $2.12 avg | 234,742 | $498K | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |